Department of Psychiatry, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Clin Psychopharmacol Neurosci. 2012 Apr;10(1):44-8. doi: 10.9758/cpn.2012.10.1.44. Epub 2012 Apr 30.
Panic disorder is characterized by recurrent panic attacks, persistent concerns about additional attacks, and worry about the implications of the attack or significant changes in behavior related to the attacks. We examined the efficacy of 24-week naturalistic, open-label escitalopram treatment in terms of the response and remission rates and functional disability in 119 adult Korean patients with panic disorder from 6 clinical centers in South Korea.
Clinical severity and functional impairment were assessed at baseline and at 4, 12, and 24 weeks after the treatment using the Panic Disorder Severity Scale and Sheehan Disability Scale. Ninety-six patients (80.7%) showed a treatment response, and 87 patients (73.1%) had attained remission after 24 weeks of escitalopram treatment.
Continuous improvement in the Panic Disorder Severity Scale and Sheehan Disability Scale scores was found over the 24 weeks of treatment.
These findings suggest that escitalopram treatment is very effective for panic disorder in terms of both response and remission rates and that long-term pharmacotherapy with escitalopram continuously improved panic symptoms and functional disability in Korean patients with panic disorder.
惊恐障碍的特征是反复发作的惊恐发作、持续的对额外发作的担忧、对发作的影响或与发作相关的行为显著变化的担忧。我们在韩国的 6 个临床中心对 119 名成年韩国惊恐障碍患者进行了为期 24 周的自然、开放性、依西酞普兰治疗的疗效研究，评估了反应和缓解率以及功能障碍。
在治疗开始后 4、12 和 24 周，使用惊恐障碍严重程度量表和 Sheehan 残疾量表评估临床严重程度和功能障碍。96 例患者（80.7%）表现出治疗反应，87 例患者（73.1%）在接受依西酞普兰治疗 24 周后达到缓解。
在 24 周的治疗过程中，惊恐障碍严重程度量表和 Sheehan 残疾量表的评分均持续改善。
这些发现表明，依西酞普兰治疗对惊恐障碍的反应和缓解率都非常有效，长期依西酞普兰药物治疗可持续改善惊恐障碍患者的惊恐症状和功能障碍。
